128 related articles for article (PubMed ID: 24735732)
1. PI3K inhibitors as potential therapeutics for autoimmune disease.
Ball J; Archer S; Ward S
Drug Discov Today; 2014 Aug; 19(8):1195-9. PubMed ID: 24735732
[TBL] [Abstract][Full Text] [Related]
2. The Role of PI3K Isoforms in Autoimmune Disease.
Ward SG
Curr Top Microbiol Immunol; 2022; 436():337-347. PubMed ID: 36243851
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.
Foster JG; Blunt MD; Carter E; Ward SG
Pharmacol Rev; 2012 Oct; 64(4):1027-54. PubMed ID: 23023033
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of phosphoinositide 3-kinase inhibitors.
Ward S; Sotsios Y; Dowden J; Bruce I; Finan P
Chem Biol; 2003 Mar; 10(3):207-13. PubMed ID: 12670534
[TBL] [Abstract][Full Text] [Related]
5. PI3 kinase inhibitors in the clinic: an update.
Kurtz JE; Ray-Coquard I
Anticancer Res; 2012 Jul; 32(7):2463-70. PubMed ID: 22753702
[TBL] [Abstract][Full Text] [Related]
6. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents.
Ward SG; Finan P
Curr Opin Pharmacol; 2003 Aug; 3(4):426-34. PubMed ID: 12901953
[TBL] [Abstract][Full Text] [Related]
7. PI3K inhibitors in cardiovascular disease.
Eisenreich A; Rauch U
Cardiovasc Ther; 2011 Feb; 29(1):29-36. PubMed ID: 20626398
[TBL] [Abstract][Full Text] [Related]
8. PI3K inhibitors in inflammation, autoimmunity and cancer.
Stark AK; Sriskantharajah S; Hessel EM; Okkenhaug K
Curr Opin Pharmacol; 2015 Aug; 23():82-91. PubMed ID: 26093105
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic applications of PI3K inhibitors in cardiovascular diseases.
Ghigo A; Morello F; Perino A; Hirsch E
Future Med Chem; 2013 Mar; 5(4):479-92. PubMed ID: 23495693
[TBL] [Abstract][Full Text] [Related]
10. Selective and potent small-molecule inhibitors of PI3Ks.
Jeong Y; Kwon D; Hong S
Future Med Chem; 2014 May; 6(7):737-56. PubMed ID: 24941870
[TBL] [Abstract][Full Text] [Related]
11. Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease.
Venable JD; Ameriks MK; Blevitt JM; Thurmond RL; Fung-Leung WP
Recent Pat Inflamm Allergy Drug Discov; 2010 Jan; 4(1):1-15. PubMed ID: 20017720
[TBL] [Abstract][Full Text] [Related]
12. Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511.
Norman MH; Andrews KL; Bo YY; Booker SK; Caenepeel S; Cee VJ; D'Angelo ND; Freeman DJ; Herberich BJ; Hong FT; Jackson CL; Jiang J; Lanman BA; Liu L; McCarter JD; Mullady EL; Nishimura N; Pettus LH; Reed AB; Miguel TS; Smith AL; Stec MM; Tadesse S; Tasker A; Aidasani D; Zhu X; Subramanian R; Tamayo NA; Wang L; Whittington DA; Wu B; Wu T; Wurz RP; Yang K; Zalameda L; Zhang N; Hughes PE
J Med Chem; 2012 Sep; 55(17):7796-816. PubMed ID: 22897589
[TBL] [Abstract][Full Text] [Related]
13. Methods to measure the enzymatic activity of PI3Ks.
Ciraolo E; Gulluni F; Hirsch E
Methods Enzymol; 2014; 543():115-40. PubMed ID: 24924130
[TBL] [Abstract][Full Text] [Related]
14. Heterocyclic compounds and their uses: a patent evaluation of WO2010151735A2.
Scozzafava A; Supuran CT
Expert Opin Ther Pat; 2011 May; 21(5):803-6. PubMed ID: 21434841
[TBL] [Abstract][Full Text] [Related]
15. Identification of highly potent and selective PI3Kδ inhibitors.
Marcoux D; Qin LY; Ruan Z; Shi Q; Ruan Q; Weigelt C; Qiu H; Schieven G; Hynes J; Bhide R; Poss M; Tino J
Bioorg Med Chem Lett; 2017 Jul; 27(13):2849-2853. PubMed ID: 28209465
[TBL] [Abstract][Full Text] [Related]
16. Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice.
Durand CA; Richer MJ; Brenker K; Graves M; Shanina I; Choi K; Horwitz MS; Puri KD; Gold MR
Autoimmunity; 2013 Feb; 46(1):62-73. PubMed ID: 23039284
[TBL] [Abstract][Full Text] [Related]
17. Phosphoinositide 3-kinases in health and disease.
Ghigo A; Morello F; Perino A; Hirsch E
Subcell Biochem; 2012; 58():183-213. PubMed ID: 22403077
[TBL] [Abstract][Full Text] [Related]
18. PI3K Signaling in Chronic Obstructive Pulmonary Disease: Mechanisms, Targets, and Therapy.
Pirozzi F; Ren K; Murabito A; Ghigo A
Curr Med Chem; 2019; 26(16):2791-2800. PubMed ID: 29557740
[TBL] [Abstract][Full Text] [Related]
19. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
Mallon R; Feldberg LR; Lucas J; Chaudhary I; Dehnhardt C; Santos ED; Chen Z; dos Santos O; Ayral-Kaloustian S; Venkatesan A; Hollander I
Clin Cancer Res; 2011 May; 17(10):3193-203. PubMed ID: 21325073
[TBL] [Abstract][Full Text] [Related]
20. The pathophysiological roles of PI3Ks and therapeutic potential of selective inhibitors in allergic inflammation.
Takeda M; Ito W; Tanabe M; Ueki S; Kihara J; Kato H; Tanigai T; Kayaba H; Sasaki T; Chihara J
Int Arch Allergy Immunol; 2010; 152 Suppl 1():90-5. PubMed ID: 20523070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
